RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aspen Pharmacare Holdings Stock

Aspen Pharmacare Holdings Net Income 2024

Aspen Pharmacare Holdings Net Income

4.4 B ZAR

Ticker

APN.JO

ISIN

ZAE000066692

WKN

A0ET80

In 2024, Aspen Pharmacare Holdings's profit amounted to 4.4 B ZAR, a -15.76% increase from the 5.23 B ZAR profit recorded in the previous year.

The Aspen Pharmacare Holdings Net Income history

YEARNET INCOME (undefined ZAR)
2027e10.27
2026e9.46
2025e8.12
20244.4
20235.23
20226.49
20214.81
20204.66
20196.46
20186.04
20175.1
20164.3
20155.2
20145.01
20133.52
20122.82
20112.58
20101.99
20091.34
20080.86
20070.72
20060.64
20050.49

Aspen Pharmacare Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aspen Pharmacare Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aspen Pharmacare Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aspen Pharmacare Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aspen Pharmacare Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aspen Pharmacare Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aspen Pharmacare Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aspen Pharmacare Holdings’s growth potential.

Aspen Pharmacare Holdings Revenue, EBIT and net profit per share

DateAspen Pharmacare Holdings RevenueAspen Pharmacare Holdings EBITAspen Pharmacare Holdings Net Income
2027e56.51 B ZAR13.14 B ZAR10.27 B ZAR
2026e53.07 B ZAR12.27 B ZAR9.46 B ZAR
2025e48.63 B ZAR10.71 B ZAR8.12 B ZAR
202444.71 B ZAR7 B ZAR4.4 B ZAR
202340.71 B ZAR8.89 B ZAR5.23 B ZAR
202238.61 B ZAR9.86 B ZAR6.49 B ZAR
202137.77 B ZAR7.84 B ZAR4.81 B ZAR
202033.66 B ZAR7.18 B ZAR4.66 B ZAR
201935.51 B ZAR8.75 B ZAR6.46 B ZAR
201838.31 B ZAR9.76 B ZAR6.04 B ZAR
201741.2 B ZAR9.6 B ZAR5.1 B ZAR
201635.6 B ZAR10.2 B ZAR4.3 B ZAR
201536.13 B ZAR8.64 B ZAR5.2 B ZAR
201429.52 B ZAR7.53 B ZAR5.01 B ZAR
201319.31 B ZAR5.11 B ZAR3.52 B ZAR
201215.26 B ZAR3.94 B ZAR2.82 B ZAR
201112.38 B ZAR3.15 B ZAR2.58 B ZAR
201010.15 B ZAR2.62 B ZAR1.99 B ZAR
20098.45 B ZAR2.18 B ZAR1.34 B ZAR
20084.88 B ZAR1.23 B ZAR863 M ZAR
20074.03 B ZAR1.08 B ZAR717 M ZAR
20063.45 B ZAR895 M ZAR638 M ZAR
20052.87 B ZAR758 M ZAR494 M ZAR

Aspen Pharmacare Holdings stock margins

The Aspen Pharmacare Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aspen Pharmacare Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aspen Pharmacare Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aspen Pharmacare Holdings's sales revenue. A higher gross margin percentage indicates that the Aspen Pharmacare Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aspen Pharmacare Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aspen Pharmacare Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aspen Pharmacare Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aspen Pharmacare Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aspen Pharmacare Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aspen Pharmacare Holdings Margin History

Aspen Pharmacare Holdings Gross marginAspen Pharmacare Holdings Profit marginAspen Pharmacare Holdings EBIT marginAspen Pharmacare Holdings Profit margin
2027e43.52 %23.25 %18.18 %
2026e43.52 %23.13 %17.83 %
2025e43.52 %22.03 %16.7 %
202443.52 %15.65 %9.85 %
202346.51 %21.83 %12.84 %
202247.42 %25.54 %16.81 %
202147.1 %20.75 %12.73 %
202050.91 %21.32 %13.86 %
201952.33 %24.64 %18.2 %
201851.38 %25.48 %15.76 %
201748.3 %23.3 %12.38 %
201650.28 %28.65 %12.08 %
201547.76 %23.93 %14.4 %
201446.49 %25.51 %16.97 %
201347.81 %26.48 %18.23 %
201247.69 %25.83 %18.47 %
201145.34 %25.43 %20.82 %
201045.37 %25.77 %19.61 %
200945.99 %25.83 %15.86 %
200845.54 %25.24 %17.68 %
200748.24 %26.75 %17.81 %
200648.13 %25.95 %18.5 %
200548.52 %26.42 %17.22 %

Aspen Pharmacare Holdings Aktienanalyse

What does Aspen Pharmacare Holdings do?

Aspen Pharmacare Holdings Ltd is a South African company that was founded in 1850 in Durban, South Africa. The company is now one of the largest manufacturers and suppliers of generic drugs in the world and employs over 10,000 people in 55 countries. The company's history dates back to its founder, William Waddell, who opened a pharmacy in Durban in 1850. Over the years, the pharmacy grew into a significant company in the region and expanded to other parts of South Africa in the 1930s. In 1997, the company was renamed Aspen Pharmacare Holdings and began focusing on the production of generic drugs. Aspen Pharma follows a diversified business model based on three pillars: generics, brands, and specialty pharmaceuticals. The company is one of the largest generic drug manufacturers in the world and offers a wide range of generics, including antibiotics, antidepressants, antidiabetics, and cardiovascular medications. The second pillar of the business model is the work in the branded pharmaceuticals sector. For this purpose, Aspen Pharmacare Holdings has a subsidiary called Aspen Global Incorporated, which is responsible for the development, approval, and marketing of patented drugs. Some of Aspen's most well-known branded products include Thrombophob, Emdocam, Bouchara-Recordati, and Zocor. The third pillar of the business model is the specialty pharmaceuticals segment. Here, the company offers medications for specific therapy areas such as cancer, multiple sclerosis, HIV/AIDS, and eye diseases. The company also has its own research and development department to develop and market new drugs. In recent years, Aspen Pharmacare Holdings has experienced impressive expansion. The company has conducted numerous acquisitions and mergers to increase its market presence and diversify its product range. An example of a significant acquisition by Aspen is the purchase of Australian company Sigma Pharmaceuticals in 2011. Through the acquisition of Sigma, Aspen was able to strengthen its role in the Australian market and improve its position in the global pharmaceutical market. In addition to manufacturing and selling drugs, the company also operates a range of other business areas. These include the production of medical devices, the development of medical technology, the manufacturing of biological drugs, and the provision of logistics and distribution services. The company is present in many third-world countries and aims to improve access to affordable medicines worldwide. Aspen has earned an excellent reputation as a pioneer in this field and has been actively involved in numerous projects and initiatives for years to improve healthcare in developing countries. In conclusion, Aspen Pharmacare Holdings is an impressive company with a long history and an extremely diverse product range. The company demonstrates strong growth dynamics while also advocating for improving public health and access to affordable medicines. Given the constantly changing healthcare industry and global threats posed by pandemics and other challenges, Aspen still has significant potential for growth, and the future looks promising. Aspen Pharmacare Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Aspen Pharmacare Holdings's Profit Margins

The profit margins of Aspen Pharmacare Holdings represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Aspen Pharmacare Holdings's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Aspen Pharmacare Holdings's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Aspen Pharmacare Holdings's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Aspen Pharmacare Holdings’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Aspen Pharmacare Holdings stock

How much profit has Aspen Pharmacare Holdings made this year?

Aspen Pharmacare Holdings has made 4.4 B ZAR this year.

How has the profit developed compared to last year?

The profit has increased by -15.76% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Aspen Pharmacare Holdings publish its earnings?

Aspen Pharmacare Holdings publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Aspen Pharmacare Holdings?

The profits of Aspen Pharmacare Holdings are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Aspen Pharmacare Holdings?

You can learn more about the earnings of Aspen Pharmacare Holdings by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Aspen Pharmacare Holdings pay?

Over the past 12 months, Aspen Pharmacare Holdings paid a dividend of 3.79 ZAR . This corresponds to a dividend yield of about 0.02 %. For the coming 12 months, Aspen Pharmacare Holdings is expected to pay a dividend of 4.06 ZAR.

What is the dividend yield of Aspen Pharmacare Holdings?

The current dividend yield of Aspen Pharmacare Holdings is 0.02 %.

When does Aspen Pharmacare Holdings pay dividends?

Aspen Pharmacare Holdings pays a quarterly dividend. This is distributed in the months of October, October, October, October.

How secure is the dividend of Aspen Pharmacare Holdings?

Aspen Pharmacare Holdings paid dividends every year for the past 7 years.

What is the dividend of Aspen Pharmacare Holdings?

For the upcoming 12 months, dividends amounting to 4.06 ZAR are expected. This corresponds to a dividend yield of 0.02 %.

In which sector is Aspen Pharmacare Holdings located?

Aspen Pharmacare Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aspen Pharmacare Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aspen Pharmacare Holdings from 9/23/2024 amounting to 0.2 ZAR, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did Aspen Pharmacare Holdings pay the last dividend?

The last dividend was paid out on 9/23/2024.

What was the dividend of Aspen Pharmacare Holdings in the year 2023?

In the year 2023, Aspen Pharmacare Holdings distributed 3.42 ZAR as dividends.

In which currency does Aspen Pharmacare Holdings pay out the dividend?

The dividends of Aspen Pharmacare Holdings are distributed in ZAR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Aspen Pharmacare Holdings

Our stock analysis for Aspen Pharmacare Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aspen Pharmacare Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.